Bet v 1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Bet v 1 in a murine immunogenicity model.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 29 07 2022
accepted: 07 09 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 26 10 2022
Statut: epublish

Résumé

There is growing concern about the toxicity of colloidal aluminum salts used as adjuvants in subcutaneous allergen immunotherapy (SCIT). Therefore, alternative adjuvants and delivery systems are being explored to replace alum in SCIT. We applied micellar elastin-like polypeptides (ELPs), a type of self-assembling protein, to replace alum as vaccine adjuvant in birch pollen SCIT. ELP and an ELP-Bet v 1 fusion protein were expressed in

Identifiants

pubmed: 36275650
doi: 10.3389/fimmu.2022.1006776
pmc: PMC9583423
doi:

Substances chimiques

aluminum sulfate 34S289N54E
Antigens, Plant 0
Immunoglobulin E 37341-29-0
Elastin 9007-58-3
Micelles 0
Aluminum CPD4NFA903
Salts 0
Allergens 0
Immunoglobulin G 0
Peptides 0
Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1006776

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM114839
Pays : United States

Informations de copyright

Copyright © 2022 van Strien, Warmenhoven, Logiantara, Makurat, Aglas, Bethanis, Leboux, van Rijt, MacKay, van Schijndel, Schneider, Olsthoorn, Jiskoot, van Ree and Kros.

Déclaration de conflit d'intérêts

HW is and JWS was an employee of HAL Allergy BV. JWS is an employee of SeraNovo BV. RR is a consultant for HAL Allergy BV, Citeq BV, Reacta Healthcare Ltd., Angany Inc., Mission MightyMe and AB Enzymes GmbH. RR reports speaker fees from HAL Allergy BV, ThermoFisher Scientific and ALK and has stock options of Angany Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Methods Enzymol. 2012;502:215-37
pubmed: 22208987
J Allergy Clin Immunol. 2011 Jun;127(6):1571-8.e9
pubmed: 21420160
J Immunol. 1999 Sep 1;163(5):2944-52
pubmed: 10453043
Biomacromolecules. 2021 Mar 8;22(3):1102-1114
pubmed: 33356170
Front Immunol. 2013 May 16;4:114
pubmed: 23720661
Eur J Immunol. 2008 Aug;38(8):2068-71
pubmed: 18651701
Allergy. 2019 May;74(5):986-995
pubmed: 30506686
Curr Allergy Asthma Rep. 2016 Jun;16(6):45
pubmed: 27221343
J Control Release. 2016 Oct 28;240:93-108
pubmed: 26578439
Front Immunol. 2020 Jun 30;11:1334
pubmed: 32714326
J Exp Med. 1989 Dec 1;170(6):2081-95
pubmed: 2531194
J Drug Target. 2016;24(4):328-39
pubmed: 26307138
Environ Sci Technol. 2009 Oct 1;43(19):7277-84
pubmed: 19848134
Int Arch Allergy Immunol. 2014;165(2):128-39
pubmed: 25412572
Polym Chem. 2014 Jan;5(5):1614-1625
pubmed: 24511327
Biomed Res Int. 2013;2013:832404
pubmed: 24175303
Mol Pharm. 2013 Feb 4;10(2):586-97
pubmed: 23301613
Front Immunol. 2013 May 31;4:129
pubmed: 23755052
Allergy. 1995 Mar;50(3):215-20
pubmed: 7545879
J Control Release. 2013 Nov 28;172(1):144-151
pubmed: 23928357
Mol Cancer Ther. 2005 Jul;4(7):1076-85
pubmed: 16020665
Protein Expr Purif. 2019 Jan;153:114-120
pubmed: 30217600
Allergy. 2019 Dec;74 Suppl 108:3-25
pubmed: 31872476
Allergy. 2012 Feb;67(2):217-26
pubmed: 22077562
Adv Drug Deliv Rev. 2016 Feb 1;97:85-100
pubmed: 26705126
J Control Release. 2015 Feb 10;199:156-67
pubmed: 25481446
J Allergy Clin Immunol. 2018 Sep;142(3):984-987.e6
pubmed: 29782896
Allergy. 2005 Aug;60(8):1021-8
pubmed: 15969682
Allergy. 2017 Oct;72(10):1461-1474
pubmed: 28474379
World Allergy Organ J. 2015 May 14;8(1):17
pubmed: 26023323
Immunol Rev. 2015 Nov;268(1):139-59
pubmed: 26497518
Protein Sci. 2012 Jun;21(6):743-50
pubmed: 22434766
Ann Allergy Asthma Immunol. 2010 Nov;105(5):328-36; quiz 337, 358
pubmed: 21055658
J Allergy Clin Immunol. 2012 Nov;130(5):1108-1116.e6
pubmed: 23021882
J Immunol. 2018 Jun 15;200(12):3897-3904
pubmed: 29728509
Eur J Immunol. 2008 May;38(5):1404-13
pubmed: 18389478
Allergy. 2019 Dec;74(12):2382-2393
pubmed: 31230350
Biomaterials. 2006 Mar;27(9):1930-5
pubmed: 16278015
J Biomed Biotechnol. 2012;2012:474605
pubmed: 22496608
Am J Respir Crit Care Med. 2011 Aug 1;184(3):303-11
pubmed: 21562124
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2792-7
pubmed: 23359691
J Exp Med. 2009 Aug 31;206(9):1941-55
pubmed: 19667059
World Allergy Organ J. 2014 Jun 03;7(1):14
pubmed: 24982698
World Allergy Organ J. 2015 Feb 28;8(1):7
pubmed: 25780491
Mucosal Immunol. 2010 May;3(3):239-46
pubmed: 20200511
Curr Allergy Asthma Rep. 2018 Feb 16;18(2):9
pubmed: 29450658
J Immunol. 1998 Jun 15;160(12):6137-44
pubmed: 9637531

Auteurs

Jolinde van Strien (J)

Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.

Hans Warmenhoven (H)

Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
R&D Department, Haarlems Allergenen Laboratorium (HAL) Allergy B.V., Leiden, Netherlands.

Adrian Logiantara (A)

Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.

Max Makurat (M)

Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.

Lorenz Aglas (L)

Division of Allergy and Immunology, Department of Biosciences, Paris Lodron University of Salzburg, Salzburg, Austria.

Athanasios Bethanis (A)

Division of Allergy and Immunology, Department of Biosciences, Paris Lodron University of Salzburg, Salzburg, Austria.

Romain Leboux (R)

Department of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, Netherlands.

Leonie van Rijt (L)

Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.

J Andrew MacKay (JA)

Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, United States.

Johannes W van Schijndel (JW)

R&D Department, Haarlems Allergenen Laboratorium (HAL) Allergy B.V., Leiden, Netherlands.

Gregory Schneider (G)

Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.

René Olsthoorn (R)

Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.

Wim Jiskoot (W)

Department of BioTherapeutics, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, Netherlands.

Ronald van Ree (R)

Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Department of Otorhinolaryngology, Amsterdam University Medical Centers, Amsterdam, Netherlands.

Alexander Kros (A)

Department of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH